Mezoo Records 2,428.25 to 1 Competition Rate in Public Offering Subscription for General Investors

by Lim Chunhan

Published 18 Mar.2026 08:22(KST)

Mezoo announced that it recorded a subscription competition rate of 2,428.25 to 1 in its public offering subscription for general investors held from March 16 to 17. The number of subscriptions reached 414,962, and the total deposit amounted to 8.8182 trillion won.

Mezoo Records 2,428.25 to 1 Competition Rate in Public Offering Subscription for General Investors

For the institutional investor demand forecast, Mezoo attracted participation from 2,320 domestic and international institutions, resulting in a competition rate of 1,108.93 to 1. The final offering price was set at 21,600 won, the upper limit of the desired price band (16,700 won to 21,600 won). Among the participating institutions, 76.5% made a commitment to hold the shares, and of these, 52.1% pledged to hold the shares for three months or longer.

Mezoo is a digital healthcare company founded by PhD researchers in biomedical engineering from Yonsei University’s Wonju Campus. The company has developed and commercialized a platform that addresses monitoring gaps inside and outside hospitals, based on biosignal measurement and analysis technology. In particular, its mobile remote patient monitoring technology, which considers patient mobility and daily environments, has helped overcome the limitations of hospital-centered monitoring, and Mezoo has been building a platform that can be further extended into patients’ daily lives in the future.

With the funds secured from this public offering, Mezoo plans to accelerate its global business expansion and advance its AI-based technology. Specifically, the company will focus on building distribution networks centered on North America and Europe; expanding local sales, marketing, and joint research; and enhancing AI-based predictive and diagnostic technologies. The strategy is to speed up its transformation into a global medical data-driven platform company. In addition, based on its partnership with Dong-A ST—a strategic investor and domestic distributor of HiCardia—the company aims to further expand its presence in the domestic hospital market.

Jungwhan Park, CEO of Mezoo, stated, “We have been developing mobile remote patient monitoring technologies that take into account patient mobility and daily living environments from the outset, and on this basis, we have demonstrated the potential for future healthcare to shift toward patient-centered monitoring. With this IPO, we intend to prove our competitiveness in the global market and enhance our corporate value through continued technological advancement.”